Theranostics Market Report by Disease Type (Neurological Disorders, Cardiovascular Diseases, Immunological Disorders, Oncology Diseases, and Others), Technology (Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Sequencing, and Others), End User (Hospitals and Clinics, Diagnostic Laboratories, and Others), and Region 2025-2033

Theranostics Market Report by Disease Type (Neurological Disorders, Cardiovascular Diseases, Immunological Disorders, Oncology Diseases, and Others), Technology (Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Sequencing, and Others), End User (Hospitals and Clinics, Diagnostic Laboratories, and Others), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A4501

Market Overview:

The global theranostics market size reached USD 2.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.9 Billion by 2033, exhibiting a growth rate (CAGR) of 16.4% during 2025-2033.

Report Attribute
Key Statistics
Base Year
2024
Forecast Years
2025-2033
Historical Years
2019-2024
Market Size in 2024 USD 2.3 Billion
Market Forecast in 2033 USD 9.9 Billion
Market Growth Rate (2025-2033) 16.4%


Theranostics is a combination of various radioactive drugs and techniques used to diagnose, deliver therapy, and treat life-threatening illnesses. It is cost-effective and involves pharmacogenetics, proteomics, and biomarker profiling. It can be integrated with nanomedicine to target specific organs and tissues and improve patient-specific outcomes. Nowadays, researchers worldwide are developing new diagnostic and therapeutic agents for theranostics to personalize the treatment of cancer, reduce side effects of treatment, and improve the quality care of pharmacotherapy.

The rising prevalence of cancer due to the increasing consumption of tobacco and alcohol, high body mass index (BMI), low nutrition intake, and lack of physical activity represents one of the main factors stimulating the market growth. Moreover, according to the World Health Organization (WHO), cancer is the second leading cause of death globally, out of which 70% of deaths occur in low and middle-income countries. This is encouraging health and governing agencies of several countries to increase awareness about the available medical treatments and improve the healthcare infrastructure, which is positively influencing the market growth. The escalating demand for personalized medicine is also bolstering the market growth. Apart from this, the integration of seamless, multiple imaging treatment technologies within a single nanoparticle to tackle pathologies is driving the market. Furthermore, the increasing approvals to produce theranostics and rising investments in research and development (R&D) activities are other factors anticipated to propel the growth of the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global theranostics market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on disease type, technology and end user.

Breakup by Disease Type:

  • Neurological Disorders
  • Cardiovascular Diseases
  • Immunological Disorders
  • Oncology Diseases
  • Others
     

Breakup by Technology:

  • Polymerase Chain Reaction
  • Immunohistochemistry
  • In-Situ Hybridization
  • Sequencing
  • Others
     

Breakup by End User:

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Others
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa


Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc (Quest Diagnostics Incorporated), Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Myriad Genetics Inc., Pfizer Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.

Report Coverage:

Report Features Details
Base Year of the Analysis 2024
 Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Disease Type, Technology, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc (Quest Diagnostics Incorporated), Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Myriad Genetics Inc., Pfizer Inc., Qiagen N.V., Thermo Fisher Scientific Inc.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

We expect the global theranostics market to exhibit a CAGR of 16.4% during 2025-2033.

The rising development of new diagnostic and therapeutic agents for theranostics for personalizing the treatment of cancer, reducing side effects of treatment, and improving the quality care of pharmacotherapy is primarily driving the global theranostics market.

The sudden outbreak of the COVID-19 pandemic had led to postponement of cancer treatments to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for theranostics.

Based on the disease type, the global theranostics market can be segmented into neurological disorders, cardiovascular diseases, immunological disorders, oncology diseases, and others. Currently, oncology diseases exhibit a clear dominance in the market.

Based on the technology, the global theranostics market has been bifurcated into polymerase chain reaction, immunohistochemistry, in-situ hybridization, sequencing, and others. Among these, polymerase chain reaction currently accounts for the majority of the total market share.

Based on the end user, the global theranostics market can be divided into hospitals and clinics, diagnostic laboratories, and others. Currently, hospitals and clinics hold the largest market share.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global theranostics market include Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc (Quest Diagnostics Incorporated), Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, F. Hoffmann-La Roche AG, General Electric Company, Illumina Inc., Myriad Genetics Inc., Pfizer Inc., Qiagen N.V., and Thermo Fisher Scientific Inc.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Theranostics Market Report by Disease Type (Neurological Disorders, Cardiovascular Diseases, Immunological Disorders, Oncology Diseases, and Others), Technology (Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Sequencing, and Others), End User (Hospitals and Clinics, Diagnostic Laboratories, and Others), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials